Immunoglobulin interface redesigning to enhance lebrikizumab mediated immunomodulation of IL-13 hyper-response
- 8 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (11), 4051-4065
- https://doi.org/10.1080/07391102.2020.1773316
Abstract
The overexpression of interleukin-13 (IL-13) leads to autoimmune and inflammatory diseases. These adverse responses can be neutralized by using lebrikizumab as a therapeutic monoclonal antibody (mAb). Herein, we have attempted to modulate the lebrikizumab mAb to enhance its binding affinity towards IL-13. The interface residues of the lebrikizumab-IL-13 complex were determined by the PyMOL and verified by the artificial neural network-based B-cell epitope prediction server (ABCpred server) and the Paratome web server. The Cologne University Protein Stability Analysis Tool (CUPSAT) web server based mutational approach was used to identify the stable and favorable interface mutations in the lebrikizumab. Only 40 mutations were selected to generate a single mutant library, and their binding affinity for IL-13 was analyzed by using the Z-Dock server. Based on high Z-score, mutants having a better affinity with IL-13 were selected to create a multi-mutant library. The multi-mutant library was again subjected to the Z-Dock server, and their binding affinity was determined. The highest-scoring ten mAb mutants were validated by using PatchDock and ClusPro servers. The best two potential mAb mutants were identified and subjected to molecular dynamics (MD) simulations to ensure its structural stability at the microscopic level. The changes in the different bonds as the effect of mutation were assessed by LigPlot + v2.1. The AllerTOP and ToxinPred web servers were used to analyze the non-allergic and nontoxic nature of the selected mutants. Therefore, these redesigned mAb could be used for potential treatment against IL-13 associated diseased conditions.Keywords
This publication has 49 references indexed in Scilit:
- In Silico Approach for Predicting Toxicity of Peptides and ProteinsPLOS ONE, 2013
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEuropean Respiratory Journal, 2012
- Antigen–antibody interface properties: Composition, residue interactions, and features of 53 non-redundant structuresBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2012
- Structural Consensus among Antibodies Defines the Antigen Binding SitePLoS Computational Biology, 2012
- Accelerating Protein Docking in ZDOCK Using an Advanced 3D Convolution LibraryPLOS ONE, 2011
- Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthmaBritish Journal of Pharmacology, 2011
- Achieving reliability and high accuracy in automated protein docking: Cluspro, PIPER, SDU, and stability analysis in CAPRI rounds 13–19Proteins: Structure, Function, and Bioinformatics, 2010
- An open‐label, single‐dose bioavailability study of the pharmacokinetics of CAT‐354 after subcutaneous and intravenous administration in healthy malesBritish Journal of Clinical Pharmacology, 2010
- Computational modeling of protein mutant stability: analysis and optimization of statistical potentials and structural features reveal insights into prediction model developmentBMC Structural Biology, 2007
- CUPSAT: prediction of protein stability upon point mutationsNucleic Acids Research, 2006